Pierfranco Spano

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7136198/publications.pdf

Version: 2024-02-01

275 papers	14,466 citations	14655 66 h-index	28297 105 g-index
278 all docs	278 docs citations	278 times ranked	11266 citing authors

#	Article	IF	Citations
1	Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet, The, 2000, 356, 2031-2036.	13.7	1,138
2	Neuroprotection by Aspirin and Sodium Salicylate Through Blockade of NF-kappa B Activation. Science, 1996, 274, 1383-1385.	12.6	776
3	Intranigral kainic acid is evidence that nigral non-dopaminergic neurones control posture. Nature, 1977, 268, 743-745.	27.8	244
4	SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinsonâ€™s disease. Brain, 2010, 133, 2032-2044.	7.6	236
5	Regulation of Dopamine D1 Receptor Trafficking and Desensitization by Oligomerization with Glutamate N-Methyl-D-aspartate Receptors. Journal of Biological Chemistry, 2003, 278, 20196-20202.	3.4	200
6	Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization. Molecular Pharmacology, 2008, 74, 59-69.	2.3	195
7	Sulpiride: A study of the effects on dopamine receptors in rat neostriatum and limbic forebrain. Life Sciences, 1975, 17, 1551-1556.	4.3	189
8	Dopamine receptors: Pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum. Life Sciences, 1978, 23, 1745-1750.	4.3	186
9	Induction of the unfolded protein response by Î±-synuclein in experimental models of Parkinsonâ€™s disease. Journal of Neurochemistry, 2011, 116, 588-605.	3.9	178
10	Effects of Rivastigmine on Cognitive Function in Dementia with Lewy Bodies: A Randomised Placebo-Controlled International Study Using the Cognitive Drug Research Computerised Assessment System. Dementia and Geriatric Cognitive Disorders, 2002, 13, 183-192.	1.5	173
11	Evidence for Inhibition by Brain Serotonin of Mouse Killing Behaviour in Rats. Nature, 1971, 233, 272-273.	27.8	169
12	Evidence for the presence of Î±₁ adrenoceptor subtypes in the human ureter. Neurourology and Urodynamics, 2005, 24, 142-148.	1.5	165
13	Review: Parkinson's disease: from synaptic loss to connectome dysfunction. Neuropathology and Applied Neurobiology, 2016, 42, 77-94.	3.2	163
14	Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection. Neuropharmacology, 1999, 38, 1477-1484.	4.1	153
15	Localization of nigral dopamine-sensitive adenylate cyclase on neurons originating from the corpus striatum. Science, 1977, 196, 1343-1345.	12.6	146
16	Opposing Roles for NF-ÎºB/Rel Factors p65 and c-Rel in the Modulation of Neuron Survival Elicited by Glutamate and Interleukin-1Î². Journal of Biological Chemistry, 2002, 277, 20717-20723.	3.4	145
17	Ketamine-Xylazine-Induced Slow (< 1.5 Hz) Oscillations in the Rat Piriform (Olfactory) Cortex Are Functionally Correlated with Respiration. Journal of Neuroscience, 2003, 23, 7993-8001.	3.6	142
18	Interleukin-1Î² and Glutamate Activate the NF-ÎºB/Rel Binding Site from the Regulatory Region of the Amyloid Precursor Protein Gene in Primary Neuronal Cultures. Journal of Biological Chemistry, 1996, 271, 15002-15007.	3.4	137

#	Article	IF	Citations
19	Dopamine Uptake is Differentially Regulated in Rat Striatum and Nucleus Accumbens. Journal of Neurochemistry, 1985, 45, 51-56.	3.9	132
20	NF-Î°B pathway: a target for preventing Î²-amyloid (AÎ²)-induced neuronal damage and AÎ²42 production. European Journal of Neuroscience, 2006, 23, 1711-1720.	2.6	131
21	Dopamine receptor sensitivity in brain and retina of rats during aging. Brain Research, 1977, 138, 565-570.	2.2	121
22	Bim and Noxa Are Candidates to Mediate the Deleterious Effect of the NF-ÂB Subunit RelA in Cerebral Ischemia. Journal of Neuroscience, 2006, 26, 12896-12903.	3.6	119
23	A dopamine-stimulated adenylate cyclase in rat substantia nigra. Journal of Neurochemistry, 1976, 27, 1565-1568.	3.9	117
24	SELECTIVE INCREASE OF BRAIN DOPAMINE INDUCED BY ?-HYDROXYBUTYRATE: STUDY OF THE MECHANISM OF ACTION. Journal of Neurochemistry, 1968, 15, 377-381.	3.9	111
25	Metabotropic glutamate receptor mRNA expression in rat spinal cord. NeuroReport, 1997, 8, 2695-2699.	1.2	109
26	Haloperidol increases and apomorphine decreases striatal dopamine metabolism after destruction of striatal dopamine-sensitive adenylate cyclase by kainic acid. Brain Research, 1977, 130, 374-382.	2.2	107
27	Glycogen synthase kinaseâ€3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production. Journal of Neurochemistry, 2011, 116, 1148-1159.	3.9	105
28	Afferent fibers mediate the increase of met-enkephalin elicited in rat spinal cord by localized pain. Pain, 1984, 18, 25-31.	4.2	102
29	Î±-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. Journal of Cell Science, 2015, 128, 2231-2243.	2.0	99
30	Aging process affects a single class of dopamine receptors. Brain Research, 1980, 202, 488-492.	2.2	98
31	Regulation of Nuclear Factor ÂB in the Hippocampus by Group I Metabotropic Glutamate Receptors. Journal of Neuroscience, 2006, 26, 4870-4879.	3.6	98
32	Effects of bromocriptine on central dopaminergic receptors. Life Sciences, 1976, 19, 225-232.	4.3	97
33	Induction of tumourâ€suppressor phosphoprotein p53 in the apoptosis of cultured rat cerebellar neurones triggered by excitatory amino acids. European Journal of Neuroscience, 1998, 10, 246-254.	2.6	97
34	Procedure for the simultaneous determination of dopamine, 3-methoxy-4-hydroxyphenylacetic acid, and 3,4-dihydroxyphenylacetic acid in brain. Analytical Biochemistry, 1971, 42, 113-118.	2.4	96
35	Attenuation of Excitatory Amino Acid Toxicity by Metabotropic Glutamate Receptor Agonists and Aniracetam in Primary Cultures of Cerebellar Granule Cells. Journal of Neurochemistry, 1993, 61, 683-689.	3.9	96
36	NFâ€ÎºB p50/RelA and câ€Relâ€containing dimers: opposite regulators of neuron vulnerability to ischaemia. Journal of Neurochemistry, 2009, 108, 475-485.	3.9	93

#	Article	IF	Citations
37	mGluR5 metabotropic glutamate receptor distribution in rat and human spinal cord: a developmental study. Neuroscience Research, 1997, 28, 49-57.	1.9	90
38	From Î±-synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's disease. Brain Research, 2012, 1476, 183-202.	2.2	89
39	Identification and Characterization of a ÎºB/Rel Binding Site in the Regulatory Region of the Amyloid Precursor Protein Gene. Journal of Biological Chemistry, 1995, 270, 26774-26777.	3.4	88
40	NF-ÎºB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid Î²-peptide toxicity. Cell Death and Differentiation, 2005, 12, 761-772.	11.2	87
41	Chapter 24 NFâ€KappaB Dimers in the Regulation of Neuronal Survival. International Review of Neurobiology, 2009, 85, 351-362.	2.0	87
42	Leptin Increases Axonal Growth Cone Size in Developing Mouse Cortical Neurons by Convergent Signals Inactivating Glycogen Synthase Kinase-3Î². Journal of Biological Chemistry, 2006, 281, 12950-12958.	3.4	86
43	Impairment of brain neurotransmitter receptors in aged rats. Mechanisms of Ageing and Development, 1980, 12, 39-46.	4.6	85
44	Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices. Molecular and Cellular Neurosciences, 2004, 25, 301-311.	2.2	84
45	Leptin Is Induced in the Ischemic Cerebral Cortex and Exerts Neuroprotection Through NF-ÎºB/c-Relâ€“Dependent Transcription. Stroke, 2009, 40, 610-617.	2.0	83
46	Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window. Neurobiology of Disease, 2013, 49, 177-189.	4.4	83
47	Opposite effects of dopamine D2 and D3 receptors on learning and memory in the rat. European Journal of Pharmacology, 1997, 336, 107-112.	3.5	82
48	Dopamine Metabolism and Receptor Function After Acute and Chronic Ethanol. Journal of Neurochemistry, 1980, 35, 34-37.	3.9	81
49	The acetylation of RelA in Lys310 dictates the NF-ÎºB-dependent response in post-ischemic injury. Cell Death and Disease, 2010, 1, e96-e96.	6.3	81
50	Nerve growth factor suppresses the transforming phenotype of human prolactinomas.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 7961-7965.	7.1	80
51	D2 dopamine receptors associated with inhibition of dopamine release from rat neostriatum are independent of cyclic AMP. Neuroscience Letters, 1986, 71, 192-196.	2.1	79
52	Glutamatergic reinnervation through peripheral nerve graft dictates assembly of glutamatergic synapses at rat skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8752-8757.	7.1	76
53	Loss of Synaptic D1 Dopamine/N-Methyl-d-aspartate Glutamate Receptor Complexes in l-DOPA-Induced Dyskinesia in the Rat. Molecular Pharmacology, 2006, 69, 805-812.	2.3	75
54	Genotype-dependent sensitivity to morphine: role of different opiate receptor populations. Brain Research, 1980, 189, 289-294.	2.2	74

#	Article	IF	Citations
55	Alphaâ€synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D₂/D₃ receptor activation. Journal of Neurochemistry, 2008, 106, 560-577.	3.9	74
56	Sodium-dependent interaction of benzamides with dopamine receptors. Brain Research, 1980, 198, 229-233.	2.2	73
57	Dopaminergic Inhibition of Prolactin Release and Calcium Influx Induced by Neurotensin in Anterior Pituitary Is Independent of Cyclic AMP System. Journal of Neurochemistry, 1986, 47, 1689-1695.	3.9	73
58	NF-ÎºB in Innate Neuroprotection and Age-Related Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 98.	2.4	73
59	Changes of ?-Endorphin and Met-Enkephalin Content in the Hypothalamus-Pituitary Axis Induced by Aging. Journal of Neurochemistry, 1983, 40, 20-24.	3.9	72
60	Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder. Urology, 2002, 60, 719-725.	1.0	72
61	The NMDA/D1 Receptor Complex as a New Target in Drug Development. Current Topics in Medicinal Chemistry, 2006, 6, 801-808.	2.1	72
62	Nerve growth factor in the anterior pituitary: localization in mammotroph cells and cosecretion with prolactin by a dopamine-regulated mechanism.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 4240-4245.	7.1	71
63	Soluble Interleukin-6 (IL-6) Receptor/IL-6 Fusion Protein Enhances in Vitro Differentiation of Purified Rat Oligodendroglial Lineage Cells. Molecular and Cellular Neurosciences, 2002, 21, 602-615.	2.2	71
64	The Contribution ofÎ±-Synuclein Spreading to Parkinsonâ€™s Disease Synaptopathy. Neural Plasticity, 2017, 2017, 1-15.	2.2	70
65	Chronic lead treatment differentially affects dopamine synthesis in various rat brain areas. Toxicology, 1979, 12, 343-349.	4.2	68
66	Dopamine D2, D3, and D4 receptor mRNA levels in rat brain and pituitary during aging. Neurobiology of Aging, 1994, 15, 713-719.	3.1	68
67	Activation of Multiple Metabotropic Glutamate Receptor Subtypes Prevents NMDA-induced Excitotoxicity in Rat Hippocampal Slices. European Journal of Neuroscience, 1996, 8, 1516-1521.	2.6	68
68	Distinct roles of diverse nuclear factor-ÎºB complexes in neuropathological mechanisms. European Journal of Pharmacology, 2006, 545, 22-28.	3.5	67
69	Nerve Growth Factor Regulates Dopamine D2 Receptor Expression in Prolactinoma Cell Lines via p75NGFR-Mediated Activation of Nuclear Factor-ÎºB. Molecular Endocrinology, 2002, 16, 353-366.	3.7	66
70	Late-onset Parkinsonism in NFÂB/c-Rel-deficient mice. Brain, 2012, 135, 2750-2765.	7.6	66
71	CHANGES IN SPECIFIC ACTIVITY OF DOPAMINE METABOLITES AS EVIDENCE OF A MULTIPLE COMPARTMENTATION OF DOPAMINE IN STRIATAL NEURONS. Journal of Neurochemistry, 1977, 28, 193-197.	3.9	65
72	L-Î±-glycerylphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. European Journal of Pharmacology, 1992, 211, 351-358.	3.5	65

#	Article	IF	Citations
73	Cannabinoid Receptor Antagonists Counteract Sensorimotor Gating Deficits in the Phencyclidine Model of Psychosis. Neuropsychopharmacology, 2007, 32, 2098-2107.	5.4	64
74	Redistribution of DAT/Î±-Synuclein Complexes Visualized by â€œIn Situâ€•Proximity Ligation Assay in Transgenic Mice Modelling Early Parkinson's Disease. PLoS ONE, 2011, 6, e27959.	2.5	62
75	Mitochondrial Dysfunction andÎ±-Synuclein Synaptic Pathology in Parkinsonâ€™s Disease: Whoâ€™s on First?. Parkinson's Disease, 2015, 2015, 1-10.	1.1	62
76	STIMULATION OF BRAIN DOPAMINE SYNTHESIS BY GAMMA-HYDROXYBUTYRATE. Journal of Neurochemistry, 1971, 18, 1831-1836.	3.9	61
77	Identification of ?-Adrenergic Receptor Binding Sites in Rat Brain Micro vessels, Using [125I]Iodohydroxybenzylpindolol. Journal of Neurochemistry, 1981, 36, 1383-1388.	3.9	61
78	Epidermal Growth Factor Induces the Functional Expression of Dopamine Receptors in the GH3 Cell Line*. Endocrinology, 1991, 128, 13-20.	2.8	61
79	Nicotine-Induced Structural Plasticity in Mesencephalic Dopaminergic Neurons Is Mediated by Dopamine D3 Receptors and Akt-mTORC1 Signaling. Molecular Pharmacology, 2013, 83, 1176-1189.	2.3	61
80	GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. Experimental Cell Research, 2014, 323, 100-111.	2.6	61
81	Preferential alterations in the mesolimbic dopamine pathway of heterozygous reeler mice: an emerging animal-based model of schizophrenia. European Journal of Neuroscience, 2002, 15, 1197-1205.	2.6	60
82	Repeated reserpine administration up-regulates the transduction mechanisms of D1 receptors without changing the density of [3H]SCH 23390 binding. Brain Research, 1989, 483, 117-122.	2.2	58
83	Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function. Current Opinion in Pharmacology, 2010, 10, 87-92.	3.5	58
84	Clozapine-Induced Alteration of Glucose Homeostasis in the Rat: The Contribution of Hypothalamic-Pituitary-Adrenal Axis Activation. Neuroendocrinology, 2007, 85, 61-70.	2.5	57
85	Subtypes of Î²-adrenergic receptors in rat cerebral microvessels. Brain Research, 1981, 220, 194-198.	2.2	56
86	Potassium channels involved in the transduction mechanism of dopamine D2 receptors in rat lactotrophs.. Journal of Physiology, 1989, 410, 251-265.	2.9	56
87	Expression of functional NR1/NR2B-type NMDA receptors in neuronally differentiated SK-N-SH human cell line. European Journal of Neuroscience, 2002, 16, 2342-2350.	2.6	56
88	Action of ethanol and salsolinol on opiate receptor function. Brain Research, 1982, 232, 506-510.	2.2	54
89	Olfaction in Parkinsonâ€™s disease: methods of assessment and clinical relevance. Journal of Neurology, 2000, 247, 88-96.	3.6	54
90	Synapsin III deficiency hampers Î±-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinsonâ€™s disease. Acta Neuropathologica, 2018, 136, 621-639.	7.7	53

#	Article	IF	Citations
91	Neuroprotection by metabotropic glutamate receptor agonists on kainate-induced degeneration of motor neurons in spinal cord slices from adult rat. Neuropharmacology, 2000, 39, 903-910.	4.1	52
92	Structural plasticity in mesencephalic dopaminergic neurons produced by drugs of abuse: critical role of BDNF and dopamine. Frontiers in Pharmacology, 2014, 5, 259.	3.5	52
93	Dopamine D2 receptor stimulation inhibits inositol phosphate generating system in rat striatal slices. Brain Research, 1988, 456, 235-240.	2.2	49
94	Characterization of Dopamine Receptors Associated with Aldosterone Secretion in Rat Adrenal Glomerulosa*. Endocrinology, 1986, 119, 2227-2232.	2.8	48
95	Characterization of tau proteins in human neuroblastoma SH-SY5Y cell line. Neuroscience Letters, 1997, 235, 149-153.	2.1	48
96	Dopamine D3 receptorâ€preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signalâ€regulated kinase phosphorylation. European Journal of Neuroscience, 2008, 28, 1231-1240.	2.6	48
97	Postâ€ischemic brain damage: NFâ€ºB dimer heterogeneity as a molecular determinant of neuron vulnerability. FEBS Journal, 2009, 276, 27-35.	4.7	48
98	Clinical Outcome After Extended Endovascular Recanalization in Buergerâ€™s Disease in 20 Consecutive Cases. Annals of Vascular Surgery, 2012, 26, 387-395.	0.9	48
99	Mitochondria and Î±-Synuclein: Friends or Foes in the Pathogenesis of Parkinsonâ€™s Disease?. Genes, 2017, 8, 377.	2.4	48
100	Genotype-dependent sensitivity to morphine: dopamine involvement in morphine-induced running in the mouse. Brain Research, 1976, 114, 536-540.	2.2	47
101	Modification of the function of D1 and D2 dopamine receptors in striatum and nucleus accumbens of rats chronically treated with haloperidol. Neuropharmacology, 1987, 26, 477-480.	4.1	47
102	Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease?. Trends in Pharmacological Sciences, 1996, 17, 155-160.	8.7	47
103	[3H]haloperidol and [3H]spiroperidol receptor binding after striatal injection of kainic acid. Neuroscience Letters, 1978, 8, 207-210.	2.1	46
104	Dopamine inhibition of neurotensin-induced increase in Ca2+ influx into rat pituitary cells. Brain Research, 1985, 347, 253-257.	2.2	46
105	A MASS FRAGMENTOGRAPHIC ASSAY OF 3-METHOXYTYRAMINE IN RAT BRAIN. Journal of Neurochemistry, 1976, 27, 795-798.	3.9	45
106	Identification and Characterization of Postsynaptic D1- and D2-Dopamine Receptors in the Cardiovascular System. Journal of Cardiovascular Pharmacology, 1988, 11, 643-650.	1.9	45
107	Should we be cautious on the use of commercially available antibodies to dopamine receptors?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 413-415.	3.0	44
108	Effects of ethanol, given during pregnancy, on the offspring dopaminergic system. Pharmacology Biochemistry and Behavior, 1983, 19, 567-570.	2.9	43

#	Article	IF	Citations
109	Identification and Characterization of Two Nuclear Factor-Î¹B Sites in the Regulatory Region of the Dopamine D2 Receptor. Endocrinology, 2007, 148, 2563-2570.	2.8	43
110	Preâ€synaptic dopamine D₃ receptor mediates cocaineâ€induced structural plasticity in mesencephalic dopaminergic neurons via ERK and Akt pathways. Journal of Neurochemistry, 2012, 120, 765-778.	3.9	43
111	Gene expression profile activated by the chemokine CCL5/RANTES in human neuronal cells. Journal of Neuroscience Research, 2004, 78, 371-382.	2.9	42
112	Brain neurotransmitter systems and chronic lead intoxication. Pharmacological Research Communications, 1980, 12, 447-460.	0.2	41
113	Chronic lead treatment induces in rat a specific and differential effect on dopamine receptors in different brain areas. Brain Research, 1981, 213, 397-404.	2.2	41
114	Identification of Neurotensin Receptors Associated with Calcium Channels and Prolactin Release in Rat Pituitary. Journal of Neurochemistry, 1986, 47, 1682-1688.	3.9	41
115	Various Ca2+ entry blockers prevent glutamate-induced neurotoxicity. European Journal of Pharmacology, 1991, 209, 169-173.	3.5	41
116	Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 5366-5371.	7.1	40
117	Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Molecular Endocrinology, 1996, 10, 272-285.	3.7	40
118	Nerve Growth Factor Regulates Dopamine D2 Receptor Expression in Prolactinoma Cell Lines via p75NGFR-Mediated Activation of Nuclear Factor-ÂB. Molecular Endocrinology, 2002, 16, 353-366.	3.7	40
119	1B/(âˆ')IRE DMT1 Expression during Brain Ischemia Contributes to Cell Death Mediated by NF-Î¹B/RelA Acetylation at Lys310. PLoS ONE, 2012, 7, e38019.	2.5	40
120	Dopaminergic and serotoninergic anorectics differentially antagonize insulin- and 2-DG-induced hyperphagia. Life Sciences, 1985, 36, 1739-1749.	4.3	39
121	Repeated administration of (âˆ') sulpiride and SCH 23390 differentially up-regulate D-1 and D-2 dopamine receptor function in rat mesostriatal areas but not in cortical-limbic brain regions. European Journal of Pharmacology, 1987, 138, 45-51.	3.5	39
122	Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Research, 2012, 1432, 95-113.	2.2	39
123	CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid. Neuroscience, 2015, 302, 112-120.	2.3	39
124	Synapsin III is a key component of Î±â€synuclein fibrils in Lewy bodies of PD brains. Brain Pathology, 2018, 28, 875-888.	4.1	37
125	Effect of chronic lead treatment on brain dopamine synthesis and serum prolactin release in the rat. Toxicology Letters, 1978, 2, 333-337.	0.8	36
126	Blockade of the Tumor Necrosis Factor-Related Apoptosis Inducing Ligand Death Receptor DR5 Prevents Î²-Amyloid Neurotoxicity. Neuropsychopharmacology, 2007, 32, 872-880.	5.4	36

#	Article	IF	Citations
127	The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes. Journal of Receptor and Signal Transduction Research, 2010, 30, 347-354.	2.5	36
128	Stimulation of serotonin synthesis by anesthetic and non-anesthetic doses of gamma-hydroxybutyrate. Pharmacological Research Communications, 1973, 5, 55-69.	0.2	35
129	The â€œIn Situâ€•Proximity Ligation Assay to Probe Proteinâ€“Protein Interactions in Intact Tissues. Methods in Molecular Biology, 2014, 1174, 397-405.	0.9	35
130	LSD and dopamine-sensitive adenylate-cyclase in various rat brain areas. Brain Research, 1975, 93, 164-167.	2.2	34
131	Nerve Growth Factor in Pituitary Development and Pituitary Tumors. Frontiers in Neuroendocrinology, 1998, 19, 128-150.	5.2	34
132	Reversal of glutamate excitotoxicity by activation of PKC-associated metabotropic glutamate receptors in cerebellar granule cells relies on NR2C subunit expression. European Journal of Neuroscience, 1999, 11, 2489-2496.	2.6	34
133	Dose-dependent and reversible effects of lead on rat dopaminergic system. Life Sciences, 1981, 28, 795-799.	4.3	33
134	Nerve growth factor signaling in prostate health and disease. Growth Factors, 2010, 28, 191-201.	1.7	33
135	Ethanol-induced changes of dopaminergic function in three strains of mice characterized by a different population of opiate receptors. Psychopharmacology, 1981, 74, 260-262.	3.1	32
136	Dopamine enhances Met-enkephalin efflux from rat striatal slices. Brain Research, 1984, 293, 364-367.	2.2	32
137	Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis. Neuroscience, 2002, 114, 91-98.	2.3	32
138	Alpha1 adrenoceptor subtypes in human urinary bladder: Sex and regional comparison. Life Sciences, 2004, 76, 417-427.	4.3	32
139	The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 529-538.	3.0	32
140	Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. Neural Plasticity, 2018, 2018, 1-15.	2.2	31
141	Serotonin and catecholamine concentrations in brain of rats injected intracerebrally with 5,6-dihydroxytryptamine. Brain Research, 1972, 44, 304-308.	2.2	30
142	Long-term effect of ovariectomy on dopamine-stimulated adenylate cyclase in rat striatum and nucleus accumbens. Psychopharmacology, 1979, 61, 13-16.	3.1	30
143	Acute and chronic ethanol administration on specific 3H-GABA binding in different rat brain areas. Psychopharmacology, 1980, 67, 261-264.	3.1	30
144	Ethanol metabolism and striatal dopamine turnover. Journal of Neural Transmission, 1982, 53, 169-177.	2.8	30

#	Article	IF	Citations
145	Postsynaptic D1 and D2 dopamine receptors are present in rabbit renal and mesenteric arteries. Neuroscience Letters, 1985, 61, 207-211.	2.1	30
146	Pharmacological characterization of D1 and D2 dopamine receptors in rat limbocortical areas. II. Dorsal hippocampus. Neuroscience Letters, 1988, 87, 253-258.	2.1	30
147	An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin. BioDrugs, 2015, 29, 285-300.	4.6	30
148	Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure. Neurochemistry International, 2015, 85-86, 14-23.	3.8	30
149	Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons. Molecular Neurobiology, 2018, 55, 1054-1067.	4.0	30
150	Metabolic fate of caudate nucleus dopamine. Brain Research, 1972, 42, 139-145.	2.2	29
151	Interaction of metergoline with striatal dopamine system. Life Sciences, 1978, 23, 2383-2391.	4.3	28
152	Effect of chronic lead treatment on gaba-ergic receptor function in rat brain. Toxicology Letters, 1980, 6, 427-432.	0.8	27
153	Effect of age on Î²-adrenergic receptors on cerebral microvessels. Brain Research, 1982, 244, 374-377.	2.2	27
154	Ontogenesis of Î±- and Î²-receptors located on cerebral microvessels. Brain Research, 1982, 242, 358-360.	2.2	27
155	Î²-adrenergic receptors in brain microvessels of diabetic rats. Life Sciences, 1984, 34, 1095-1100.	4.3	27
156	Distribution and kainate-mediated induction of the DNA mismatch repair protein MSH2 in rat brain. Neuroscience, 1999, 94, 1323-1331.	2.3	27
157	Glutamatergic innervation of rat skeletal muscle by supraspinal neurons: a new paradigm in spinal cord injury repair. Current Opinion in Neurobiology, 2006, 16, 323-328.	4.2	27
158	Bromocriptine and lisuride stimulate the accumulation of cyclic AMP in intact slices but not in homogenates of rat neostriatum. Neuroscience Letters, 1979, 14, 31-36.	2.1	26
159	The End Is the Beginning: Parkinsonâ€™s Disease in the Light of Brain Imaging. Frontiers in Aging Neuroscience, 2017, 9, 330.	3.4	26
160	Synergistic Association of Valproate and Resveratrol Reduces Brain Injury in Ischemic Stroke. International Journal of Molecular Sciences, 2018, 19, 172.	4.1	26
161	Chronic lead exposure differentially affects dopamine transport in rat striatum and nucleus accumbens. Toxicology, 1984, 33, 81-90.	4.2	25
162	Neuroprotective effect of thyrotropin-releasing hormone against excitatory amino acid-induced cell death in hippocampal slices. European Journal of Pharmacology, 1999, 370, 133-137.	3.5	25

#	Article	IF	Citations
163	The tyrosine phosphatase Shpâ€2 interacts with the dopamine D₁ receptor and triggers D₁â€mediated Erk signaling in striatal neurons. Journal of Neurochemistry, 2011, 117, 253-263.	3.9	25
164	The Î³-Secretase Modulator CHF5074 Reduces the Accumulation of Native Hyperphosphorylated Tau in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2011, 45, 22-31.	2.3	25
165	Chronic lead treatment affects dopaminergic control of prolactin secretion in rat pituitary. Toxicology Letters, 1984, 20, 237-241.	0.8	24
166	Evidence for the presence of D2 but not D1 dopamine receptors in rat hypothalamic perifornical area. Neuroscience Letters, 1986, 67, 159-162.	2.1	24
167	Different muscarinic receptor subtypes modulate proliferation of primary human detrusor smooth muscle cells via Akt/PI3K and map kinases. Pharmacological Research, 2013, 74, 1-6.	7.1	24
168	Evidence for the presence of D1 and D2 dopamine receptors in the rat adrenal cortex. European Journal of Pharmacology, 1985, 109, 315-316.	3.5	23
169	PEA and luteolin synergistically reduce mast cell-mediated toxicity and elicit neuroprotection in cell-based models of brain ischemia. Brain Research, 2016, 1648, 409-417.	2.2	23
170	Effect of chronic ethanol treatment on adenylate cyclase activity in rat striatum. Neuroscience Letters, 1983, 40, 187-192.	2.1	22
171	Stimulation of dopamine D-2 receptors increases potassium permeability in mammotrophs. European Journal of Pharmacology, 1987, 139, 361-362.	3.5	22
172	Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas. British Journal of Cancer, 1995, 72, 1397-1399.	6.4	22
173	Inhibition of Glutamate-induced Neurotoxicity by a Tau Antisense Oligonucleotide in Primary Culture of Rat Cerebellar Granule Cells. European Journal of Neuroscience, 1995, 7, 1603-1613.	2.6	22
174	Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145. European Journal of Endocrinology, 2002, 147, 407-415.	3.7	22
175	Presenilin 2 mutations alter cystatin C trafficking in mouse primary neurons. Neurobiology of Aging, 2007, 28, 371-376.	3.1	22
176	Different neurotransmitter systems are involved in the development of esophageal achalasia. Life Sciences, 1995, 56, 1311-1320.	4.3	21
177	Identification of novel alternatively-spliced mRNA isoforms of metabotropic glutamate receptor 6 gene in rat and human retina. Gene, 2001, 262, 99-106.	2.2	21
178	Activation of NF-ÎºB p65/c-Rel dimer is associated with neuroprotection elicited by mGlu5 receptor agonists against MPP+ toxicity in SK-N-SH cells. Journal of Neural Transmission, 2008, 115, 669-676.	2.8	21
179	Neuronal mechanisms regulating ethanol effects on the dopaminergic system. Life Sciences, 1982, 30, 2163-2170.	4.3	20
180	Immunoreactive met-enkephalin plasma concentrations in chronic alcoholics and in children born from alcoholic mothers. Life Sciences, 1983, 33, 1581-1586.	4.3	20

#	Article	IF	Citations
181	Opposing regulation of amyloid precursor protein by ionotropic and metabotropic glutamate receptors. NeuroReport, 1995, 6, 1317-1321.	1.2	20
182	Gene expression profile of prostate cancer cell lines: Effect of nerve growth factor treatment. Molecular and Cellular Endocrinology, 2008, 284, 11-20.	3.2	20
183	Role of receptor heterodimers in the development of l-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, S159-S164.	2.2	20
184	Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype. Endocrinology, 1994, 135, 290-298.	2.8	20
185	Prolactin releasing effect of sulpiride isomers in rats and man. Journal of Neural Transmission, 1979, 46, 205-214.	2.8	19
186	Effect of lead exposure on dopaminergic receptors in rat striatum and nucleus accumbens. Brain Research, 1986, 381, 138-142.	2.2	19
187	Muscarinic receptors stimulate cell proliferation in the human urothelium-derived cell line UROtsa. Pharmacological Research, 2011, 64, 420-425.	7.1	19
188	Lack of correlation between the neurochemical and behavioural effects induced by d-amphetamine in chronically lead-treated rats. Neuropharmacology, 1980, 19, 795-799.	4.1	18
189	Hormonal imputs and brain tryptophan metabolism: The effect of growth hormone. Experientia, 1975, 31, 384-386.	1.2	17
190	Characterization of dopamine receptors in various species of invertebrates and vertebrates. Neuroscience, 1981, 6, 2077-2079.	2.3	17
191	Pharmacological characterization of D1 and D2 dopamine receptors in rat limbocortical areas. I. Frontal cortex. Neuroscience Letters, 1988, 87, 247-252.	2.1	17
192	Rat pituitary cells selectively express mRNA encoding the short isoform of the Î³2 GABAA receptor subunit. Molecular Brain Research, 1992, 13, 145-150.	2.3	17
193	Sex-related variations in serum nerve growth factor concentration in humans. Neuropeptides, 2002, 36, 391-395.	2.2	17
194	The inhibitor of IkappaBalpha phosphorylation BAY 11-7082 prevents NMDA neurotoxicity in mouse hippocampal slices. Neuroscience Letters, 2005, 377, 147-151.	2.1	17
195	Antisense Strategy Unravels a Dopamine Receptor Distinct from the D2 Subtype, Uncoupled with Adenylyl Cyclase, Inhibiting Prolactin Release from Rat Pituitary Cells. Journal of Neurochemistry, 1994, 62, 1260-1266.	3.9	17
196	Glutamatergic Reinnervation and Assembly of Glutamatergic Synapses in Adult Rat Skeletal Muscle Occurs at Cholinergic Endplates. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1103-1115.	1.7	17
197	Effects of GTP and sodium on rat striatal dopamine receptors labeled with lisuride. Brain Research, 1982, 248, 185-187.	2.2	16
198	Opposing regulation of tau protein levels by ionotropic and metabotropic glutamate receptors in human NT2 neurons. Neuroscience Letters, 1998, 243, 77-80.	2.1	16

#	Article	IF	Citations
199	Combined Î±2-adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle. Psychopharmacology, 2001, 159, 105-110.	3.1	16
200	Spinal cord mGlu1a receptorsPossible target for amyotrophic lateral sclerosis therapy. Pharmacology Biochemistry and Behavior, 2002, 73, 447-454.	2.9	16
201	Detection of muscarinic receptor subtypes in human urinary bladder mucosa: Age and genderâ€dependent modifications. Neurourology and Urodynamics, 2008, 27, 421-428.	1.5	16
202	STEREOSPECIFIC EFFECTS OF (-)SULPIRIDE ON BRAIN DOPAMINE METABOLISM AND PROLACTIN RELEASE. Journal of Neurochemistry, 1979, 32, 1547-1550.	3.9	15
203	Differential effect of reserpine on dopaminergic receptor function in rat substantia nigra and caudate nucleus. Brain Research, 1979, 160, 553-558.	2.2	15
204	Identification of D-2 dopaminergic receptors in bovine adrenal cortex. Life Sciences, 1985, 37, 2539-2548.	4.3	15
205	Dopaminergic Regulation of Aldosterone Secretion. American Journal of Hypertension, 1990, 3, 93S-95S.	2.0	15
206	Growth factors in pituitary tumors. Pituitary, 1999, 1, 153-158.	2.9	15
207	Low doses of l-sulpiride down-regulate striatal and cortical dopamine receptors and Î²-adrenoceptors. European Journal of Pharmacology, 1991, 199, 247-253.	3.5	14
208	Activation of Dopamine D2 Receptors Linked to Voltage-Sensitive Potassium Channels Reduces Forskolin-Induced Cyclic AMP Formation in Rat Pituitary Cells. Journal of Neurochemistry, 1992, 59, 1829-1835.	3.9	14
209	Differential expression of fetal and mature tau isoforms in primary cultures of rat cerebellar granule cells during differentiation in vitro. Molecular Brain Research, 1995, 34, 38-44.	2.3	14
210	Effects of olanzapine on glucose transport, proliferation and survival in C2C12 myoblasts. Molecular and Cellular Endocrinology, 2008, 292, 42-49.	3.2	14
211	NFâ€ÎºB and epigenetic mechanisms as integrative regulators of brain resilience to anoxic stress. Brain Research, 2012, 1476, 203-210.	2.2	14
212	Striatal adenylate cyclase-inhibiting dopamine D2 receptors are not affected by the aging process. Neuroscience Letters, 1987, 75, 38-42.	2.1	13
213	Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases. Handbook of Experimental Pharmacology, 2017, 245, 85-110.	1.8	13
214	Interaction of sulpiride and ergot derivatives on rat brain DOPAC concentration and prolactin secretion in vivo. European Journal of Pharmacology, 1979, 56, 15-20.	3.5	12
215	Age related changes of enkephalin in rat spinal cord. Brain Research, 1983, 262, 160-162.	2.2	12
216	Dihydroergotoxine decreases blood pressure in spontaneously hypertensive rats by interacting with peripheral dopamine receptors. Life Sciences, 1985, 36, 1515-1522.	4.3	12

#	Article	IF	Citations
217	Effect of temperature and ionic environment on the specific binding of 3H(â€")sulpiride to membranes from different rat brain regions. Neurochemistry International, 1985, 7, 279-284.	3.8	12
218	Selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis impairs prepulse inhibition of acoustic startle. Neuroscience, 2001, 108, 299-305.	2.3	12
219	Alternative splicing of mGlu6 gene generates a truncated glutamate receptor in rat retina. NeuroReport, 2001, 12, 2711-2715.	1.2	12
220	Nerve growth factor and retinoic acid interactions in the control of small cell lung cancer proliferation. European Journal of Endocrinology, 2002, 147, 371-379.	3.7	12
221	Selective disarrangement of the rostral telencephalic cholinergic system in heterozygous reeler mice. Neuroscience, 2007, 144, 834-844.	2.3	12
222	Rat dopaminergic function in the retina during aging. Neurobiology of Aging, 1981, 2, 229-231.	3.1	11
223	Central toxic effects of chronic ethanol treatment: Actions on GABA and benzodiazepine recognition sites. Toxicology Letters, 1982, 13, 99-103.	0.8	11
224	Tolerance to some behavioural effects of lisuride, a dopamine receptor agonist, and reverse tolerance to others, after repeated administration. Neuropharmacology, 1985, 24, 199-206.	4.1	11
225	Repeated administration of lisuride down-regulates dopamine D-2 receptor function in mesostriatal and in mesolimbocortical rat brain regions. European Journal of Pharmacology, 1990, 176, 85-90.	3.5	11
226	Priming of cultured neurons with sabeluzole results in long-lasting inhibition of neurotoxin-induced tau expression and cell death. , 1997, 26, 95-103.		11
227	Targeting IKK2 by pharmacological inhibitor AS602868 prevents excitotoxic injury to neurons and oligodendrocytes. Journal of Neural Transmission, 2008, 115, 693-701.	2.8	11
228	Depletion of Progranulin Reduces GluN2B-Containing NMDA Receptor Density, Tau Phosphorylation, and Dendritic Arborization in Mouse Primary Cortical Neurons. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 164-175.	2.5	11
229	Reversal by the selective D-2 dopamine receptor blocker sulpiride of the hypotensive effect of co-dergocrine in elderly hypertensives. European Journal of Clinical Pharmacology, 1987, 33, 519-521.	1.9	10
230	Evidence for the presence of both D-1 and D-2 dopamine receptors in human esophagus. Life Sciences, 1990, 47, 447-455.	4.3	10
231	Opposing roles for D-1 and D-2 dopamine receptors in the regulation of lower esophageal sphincter motility in the rat. Life Sciences, 1994, 54, 1035-1045.	4.3	10
232	Î±-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate and kainate differently affect neuronal cytoarchitecture of rat cerebellar granule cells. Neuroscience Letters, 1994, 166, 77-80.	2.1	10
233	Epidermal Growth Factor Promotes Uncoupling from Adenylyl Cyclase of the Rat D_{2S} Receptor Expressed in GH4C1 Cells. Journal of Neurochemistry, 1994, 62, 907-915.	3.9	10
234	Effect of desmethyldiazepam and chlordesmethyldiazepam on 3?,5?-cyclic guanosine monophosphate levels in rat cerebellum. Psychopharmacology, 1976, 50, 241-244.	3.1	9

#	Article	IF	Citations
235	Functional interaction between receptors for dopamine antagonists and GABA central receptors. Life Sciences, 1978, 23, 1751-1756.	4.3	9
236	Properties of benzodiazepine binding sites in peripheral blood lymphocytes. Journal of Clinical Laboratory Analysis, 1989, 3, 332-336.	2.1	9
237	Differential effect of acute reserpine administration on D-1 and D-2 dopaminergic receptor density and function in rat striatum. Neurochemistry International, 1989, 14, 61-64.	3.8	9
238	Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model. Pharmacological Research, 2015, 102, 12-21.	7.1	9
239	Inhibition of the aldosterone response to sodium depletion in man by stimulation of dopamine DA2 receptors. European Journal of Clinical Pharmacology, 1988, 35, 323-326.	1.9	8
240	Vasoactive intestinal polypeptide (VIP) selectively stimulates prolactin release in healthy women. Gynecological Endocrinology, 1988, 2, 11-18.	1.7	8
241	A Mechanism Additional to Cyclic AMP Accumulation for Vasoactive Intestinal Peptide-Induced Prolactin Release. Neuroendocrinology, 1990, 51, 481-486.	2.5	8
242	Effect of right middle cerebral artery occlusion on striatal dopaminergic function. Journal of Neural Transmission, 1982, 53, 257-264.	2.8	7
243	Release of Met-enkephalin from rat striatal slices: effect of amphetamine and fipexide. Brain Research, 1986, 398, 212-214.	2.2	7
244	Angiotensin II differentially affects cyclic AMP formation in intact adrenal glomerulosa cells and in purified membrane preparations. Regulatory Peptides, 1989, 24, 167-178.	1.9	7
245	Increased serum concentration of nerve growth factor in patients with microprolactinoma. Neuropeptides, 2004, 38, 21-24.	2.2	7
246	Influence of clofibrate on serum triptophan in man. Research in Experimental Medicine, 1974, 163, 265-269.	0.7	6
247	The influence of dopamine on the incorporation of different sugars into total proteins of hippocampal slices. Pharmacology Biochemistry and Behavior, 1980, 13, 303-304.	2.9	6
248	Molecular and pharmacological detection of dopaminergic receptors in the human male urinary tract. Neurourology and Urodynamics, 2009, 28, 343-348.	1.5	6
249	Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation. International Journal of Molecular Sciences, 2017, 18, 184.	4.1	6
250	Decreased content of met-enkephalin-like peptides in superior cervical and coeliac ganglia of aged rats. Neurobiology of Aging, 1983, 4, 147-149.	3.1	5
251	Antisense strategy unravels tau proteins as molecular risk factors for glutamate-induced neurodegeneration. Cellular and Molecular Neurobiology, 1994, 14, 569-578.	3.3	5
252	Tau protein immunolocalization in fetal and adult human spinal cord. Neuroscience Research, 1995, 22, 197-202.	1.9	5

#	Article	IF	Citations
253	Volume Transmission and the Russian-Doll Organization of Brain Cell Networks. , 2014, , 103-119.		5
254	Inhibitory effects of cyclic-AMP dependent protein kinase on guanylate cyclase activity in rat cerebellum. FEBS Letters, 1978, 93, 231-234.	2.8	4
255	Chronic lead exposure alters dopaminergic mechanisms in rat pituitary. Toxicology Letters, 1986, 32, 255-260.	0.8	4
256	N-methyl-d-aspartate neurotoxicity in hippocampal slices: protection by aniracetam. European Journal of Pharmacology, 1995, 275, 311-314.	3.5	4
257	Immature neuronal phenotype derived from mouse skin precursor cells differentiated in vitro. Brain Research, 2006, 1109, 32-36.	2.2	4
258	Involvement of Target Gene Polymorphisms in 5-Fluorouracil Toxicity: A Case Report. Pharmacology, 2012, 89, 99-102.	2.2	4
259	Effect of reserpine on adenylate cyclase system of rat striatum. Neurochemical Research, 1976, 1, 329-336.	3.3	3
260	Tolerance to hypoactivity and sensitization to hyperactivity after chronic treatment with a presynaptic dose of lisuride in rats. European Journal of Pharmacology, 1992, 216, 81-86.	3.5	3
261	[No Title]. British Journal of Psychiatry, 1993, 163, 693-694.	2.8	3
262	Glutamatergic Neurons Induce Expression of Functional Glutamatergic Synapses in Primary Myotubes. PLoS ONE, 2012, 7, e31451.	2.5	3
263	Differential up-regulation of D-1 and D-2 dopamine receptor function in mesostriatal areas but not in cortical-limbic brain regions of rats chronically treated with (?)sulpiride and SCH 23390. Drug Development Research, 1987, 11, 243-249.	2.9	2
264	Deafferentation induces early and delayed differential changes in the pattern of expression of the various guanine nucleotide binding protein mRNAs in rat striatum. Neuroscience Letters, 1993, 164, 109-112.	2.1	2
265	Molecular mechanisms of glutamate-induced neurodegeneration. International Review of Psychiatry, 1995, 7, 339-348.	2.8	2
266	Increase of aldosterone secretion following acute haloperidol administration. International Clinical Psychopharmacology, 1996, 11, 67.	1.7	2
267	Evidence for the presence of D1 and D2 dopamine receptors in rat oesophagus. Pharmacological Research, 1989, 21, 123-124.	7.1	1
268	Effects of chronic treatment with L-alpha-glycerylphosphorylcholine on hippocampal cholinergic transmission in the rat. Drug Development Research, 1992, 27, 277-286.	2.9	1
269	Science, medicine and Golgi. Nature Medicine, 1995, 1, 386-386.	30.7	1
270	Activation of Opioid Receptors Inhibits Neuronal-like Calcium Channels, Distal Steps of Secretion, and Cell Proliferation in Human Small Cell Lung Carcinoma Cellsa. Annals of the New York Academy of Sciences, 1998, 841, 646-650.	3.8	1

#	Article	IF	Citations
271	Preface. Progress in Brain Research, 2014, 211, ix.	1.4	1
272	A superfusion method for the study of calcium fluxes from pituitary cells. Journal of Pharmacological Methods, 1988, 19, 263-266.	0.7	0
273	Industrialists set up first school of molecular medicine. Journal of Molecular Medicine, 1995, 73, 151-151.	3.9	0
274	Downregulation of Nicotinic Acetylcholine Receptors by Nerve Growth Factor in Human Small Cell Lung Carcinoma Cell Linesa. Annals of the New York Academy of Sciences, 1998, 841, 651-654.	3.8	0
275	Oligomerization of Dopamine D1 and Glutamate NMDA Receptors: A New Mechanism Regulating Striatal Function. , 2005, , 141-149.		0